Printer Friendly

Merck signs collaboration and licensing agreement with Domain Therapeutics.

M2 EQUITYBITES-January 25, 2017-Merck signs collaboration and licensing agreement with Domain Therapeutics

(C)2017 M2 COMMUNICATIONS http://www.m2.com

United States-based Merck has signed a collaboration and licensing agreement with France-based Domain Therapeutics.

It was reported yesterday that the contract has been signed to explore the potential of adenosine inhibition in the development of novel immuno-oncology agents. The partnership is claimed to strengthen combination strategy in immuno-oncology, and underscore Merck KGaA, Darmstadt, Germany's science-driven approach to discovering and developing novel compounds through both internal capabilities and external collaborations.

Adenosine receptor antagonists are small molecules thought to slow tumour progression and improve the response to combination immunotherapies by inhibiting adenosine - a compound generated by cancer cells that inhibits anti-tumour responses by binding to T cells.

The contract will include a close collaboration between both parties to develop and test new agents targeting key adenosine receptors. Merck will support research activities and receive global rights to Domain Therapeutics' next generation of adenosine receptor inhibitors.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2017 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Date:Jan 25, 2017
Words:174
Previous Article:Immune Pharmaceuticals collaborates with SATT Sud-Est.
Next Article:Actelion fails to meet primary goal in Phase III study evaluating macitentan.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters